A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
Ahmed M I Elfiky(GlaxoSmithKline (United Kingdom)), Wouter J. de Jonge(University of Bonn), Ivan Ting Hin Fung(Amsterdam University Medical Centers), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), Rebecca C. Furze(Age UK), Manon E. Wildenberg(Amsterdam UMC Location University of Amsterdam), Ishtu Hageman(Amsterdam University Medical Centers), V Joustra(Amsterdam University Medical Centers), Jan Verhoeff, Christianne J. Buskens(Amsterdam Neuroscience), Inmaculada Rioja(Bicycle Therapeutics (United Kingdom)), Nicholas Smithers(GlaxoSmithKline (United Kingdom)), Lieven Mulders(Amsterdam University Medical Centers), Palwinder K. Mander(Age UK), Andrew Y. F. Li Yim(Amsterdam University Medical Centers), Matthew Bell(GlaxoSmithKline (United Kingdom)), Geert D’Haens(Amsterdam University Medical Centers), Marte Becker
Cited by 7
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway
|Nature Immunology|2005|1.1k
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
|Gastroenterology|1998|865